Table 1.
Type of ATCT | Characters | Advantages | Disadvantages | Comments |
---|---|---|---|---|
LAK cells | Non-specific. Non-MHC-restricted |
Modest efficacy in melanoma, RCC, and glioma through systematic administration or intralesional injection | High toxicity. Limited expansion in vitro Low cytotoxicity |
Almost abandoned |
CIK cells | Non-specific. Non-MHC-restricted |
Improved cytotoxicity VS LAKs. Low toxicity |
The definite conclusion about the clinical efficacy of CIKs is unclear | Potential applicability in various solid tumors |
TILs | Specific | Most effective treatment for metastatic melanoma | Candidature only accepted when the tumor is resectable Requirement of immunodepleting preparation |
Limited application in other solid tumors |
TCR-T cells | Specific MHC-restricted |
High avidity to tumor cells Long-lasting responses |
Limited identified TAAs “On-target, off-organ” effects |
Potential applicability in various solid tumors |
CAR-T cells | Specific Non-MHC-restricted |
Wide range of potential target TAAs High avidity to tumor cells Long-lasting responses |
“On-target, off-organ” effects | Potential applicability in various solid tumors |